Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Massachusetts General Hospital
M.D. Anderson Cancer Center
Mayo Clinic
University of Nebraska
Mayo Clinic
M.D. Anderson Cancer Center
Acerta Pharma BV
H. Lee Moffitt Cancer Center and Research Institute
Thomas Jefferson University
Case Comprehensive Cancer Center
Thomas Jefferson University
Thomas Jefferson University
Memorial Sloan Kettering Cancer Center
National Institutes of Health Clinical Center (CC)
University of Colorado, Denver
Barbara Ann Karmanos Cancer Institute
Masonic Cancer Center, University of Minnesota
City of Hope Medical Center
Columbia University
Fred Hutchinson Cancer Center
Thomas Jefferson University
Masonic Cancer Center, University of Minnesota
Thomas Jefferson University
Thomas Jefferson University
Thomas Jefferson University
Cedars-Sinai Medical Center
Ohio State University Comprehensive Cancer Center
Cedars-Sinai Medical Center
Advice Pharma Group srl
Mundipharma Research Limited
Roswell Park Cancer Institute
OHSU Knight Cancer Institute
Memorial Sloan Kettering Cancer Center
Beth Israel Deaconess Medical Center
Washington University School of Medicine
University of Nebraska
University of Nebraska
University of Birmingham
Northside Hospital, Inc.
Case Comprehensive Cancer Center
M.D. Anderson Cancer Center
Fred Hutchinson Cancer Center
University of Virginia
Scripps Health
Columbia University
Thomas Jefferson University
University of Liege
H. Lee Moffitt Cancer Center and Research Institute
Northwestern University